Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its price target lifted by Needham & Company LLC from $68.00 to $98.00 in a report published on Tuesday. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on the stock. Jefferies Group LLC reissued a buy rating and issued a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, June 22nd. Piper Jaffray Companies reissued an overweight rating and issued a $126.00 price objective (up previously from $116.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, June 21st. BidaskClub raised shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, June 13th. ValuEngine raised shares of Alnylam Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 13th. Finally, Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, June 12th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of Buy and an average target price of $76.03.
Shares of Alnylam Pharmaceuticals (ALNY) traded up 0.18% during trading on Tuesday, reaching $79.97. 1,082,066 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $84.18. The company’s market capitalization is $6.89 billion. The stock has a 50-day moving average of $67.47 and a 200-day moving average of $51.64.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business had revenue of $19 million during the quarter, compared to analyst estimates of $22.91 million. During the same period in the previous year, the company earned ($1.21) EPS. Alnylam Pharmaceuticals’s revenue was up 160.3% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals will post ($5.29) EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last quarter. 4.30% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Manhattan Co. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $135,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $148,000. Westpac Banking Corp acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $202,000. Prudential Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $215,000. Finally, Nisa Investment Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $256,000. Hedge funds and other institutional investors own 89.27% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/alnylam-pharmaceuticals-inc-alny-given-new-98-00-price-target-at-needham-company-llc/1947162.html
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.